This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Aroplatin

Agenus Inc.

Drug Names(s): L-NDDP

Description: Aroplatin is a liposomal formulation of an advanced platinum chemotherapeutic similar to Eloxatin. Aroplatin is designed to overcome the toxicity and drug resistance associated with current platinum-based chemotherapeutics. Research has shown that liposome encapsulation can increase a treatment’s bioavailability, extending the treatment’s effect; help reduce the damaging effects of some drugs on healthy tissues, markedly improving a treatment’s safety profile; and accumulate at the site of a tumor, delivering higher concentrations of the drug to the disease target.

Deal Structure: Aroplatin was originally developed by Aronex.

In 2001, Antigenics acquired Aronex.


Aroplatin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug